The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Is nedocromil sodium effective treatment for asthma?
Open accessAbstract
In the past decade, the Lreaune nt of usLhma has changed. This evolution occurred with the realization that prevention of regular asthma symptoms is preferable to treatme nt of asthmatic symptoms when they develop. Thi s unders tanding is reflected in the consensus reports on asthma management , which have rece ntly been publi shed in several countries ll-41 . These reports agree that the main aim of management is to keep asthmatic patients functioning as c lose to normal. f()r as muc h of the rime, as possible. With this in mind, the currently available drugs to treat asthma, for practical purposes, fall into two classes: those which are most useful to treat symptoms when they develop (such as P 2 -agonists or theophylline), and those which are most useful in preventing regular sympLOms and exaccrbat ions of asthma from occ uring (suc h as inhaled corticos te roids or cromoglycate). Whilst this division is somewhat artificial, (for example, inhaled P2-agonists are very useful for preventing exerc iseinduced bronc hoconsLriction) . the distinction between these c lasses of drugs IHL~ practical importance, as inhal ed corticosteroids or c rorn-oglycate arc now recomme nded as the most appropriate regular maintenance treatment for asthmatic patients witb anything o ther than infrequent symptoms [1-4]. A recent addition to the physicians therapeutic armament for asthma treatment is nedocromil sodium, which was originally developed as an agent which would inhibit the release of mediators from inflammatory cells present in the airways of all (even mild, stable) asthmatics. The drug was developed as an extension of cromolyn, which was thought at the time to have similar pharmacological properties. It was hoped that nedocromil would have significant therapeutic advantages, but would retain the low side-effect profile of cromolyn. Nedocromil has been extensively studied in asthma, and the results of all known published and unpublished, placebo-controlled, double-blind, randomized clinical trials have been incorporated into a metaanalysis by EowARDS and STEVENS [5]. These authors are associated with the company which has developed and marketed nedocromil and, thereby, have access to all available clinical trials, including unpublished data,
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Publication prejudices: An experimental study of confirmatory bias in the peer review system
Mahoney, M. J. (1977) · Cognitive Therapy and Research · doi:10.1007/bf01173636 · Cited by 1,013
The Medical Review Article: State of the Science
MULROW, C. D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-3-485 · Cited by 856
Cited by
Bestall, J. C., Paul, E. A., Garrod, R., Garnham, R., Jones, P. W., & Wedzicha, J. A. (1999) · Thorax · doi:10.1136/thx.54.7.581 · Cited by 2,927
Swanney, M. P., Ruppel, G., Enright, P. L., Pedersen, O. F., Crapo, R. O., Miller, M. R., Jensen, R. L., Falaschetti, E., Schouten, J. P., Hankinson, J. L., et al. (2008) · Thorax · doi:10.1136/thx.2008.098483 · Cited by 535
Hall, G. L., Filipow, N., Ruppel, G., Okitika, T., Thompson, B., Kirkby, J., Steenbruggen, I., Cooper, B. G., & Stanojevic, S. (2021) · European Respiratory Journal · doi:10.1183/13993003.00289-2020 · Cited by 416
Ongoing airway inflammation in patients with COPD who do not currently smoke
Rutgers, S. R. (2000) · Thorax · doi:10.1136/thorax.55.1.12 · Cited by 398
Clinical COPD phenotypes: a novel approach using principal component and cluster analyses
Burgel, P.-R., Paillasseur, J.-L., Caillaud, D., Tillie-Leblond, I., Chanez, P., Escamilla, R., Court-Fortune, I., Perez, T., Carré, P., & Roche, N. (2010) · European Respiratory Journal · doi:10.1183/09031936.00175109 · Cited by 358
Metadata
- Authors
- O'Byrne, P., & Cook, D.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 1993-01-01
- Volume
- 6
- Issue
- 1
- Pages
- 5-6
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W1891990519
- Cited by
- 223
- References
- 2
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is nedocromil sodium effective treatment for asthma? https://app.cochat.ai/papers/10.1183/09031936.93.06010005
- The paper
- O'Byrne, P., & Cook, D. (1993). Is nedocromil sodium effective treatment for asthma? European Respiratory Journal. https://doi.org/10.1183/09031936.93.06010005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.